Vor Biopharma, Inc. (VOR)
18.03
-1.31
(-6.77%)
USD |
NASDAQ |
Oct 16, 16:00
17.73
-0.30
(-1.66%)
After-Hours: 20:00
Vor Biopharma Enterprise Value : 518.59M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 518.59M |
| October 15, 2026 | 589.92M |
| October 14, 2026 | 557.79M |
| October 13, 2026 | 574.68M |
| October 12, 2026 | 614.97M |
| October 09, 2026 | 620.42M |
| October 08, 2026 | 578.49M |
| October 07, 2026 | 559.43M |
| October 06, 2026 | 533.83M |
| October 05, 2026 | 548.54M |
| October 02, 2026 | 554.53M |
| October 01, 2026 | 520.22M |
| September 30, 2026 | 575.76M |
| September 29, 2026 | 534.92M |
| September 28, 2026 | 533.83M |
| September 25, 2026 | 545.27M |
| September 24, 2026 | 540.91M |
| September 23, 2026 | 591.56M |
| September 22, 2026 | 734.78M |
| September 21, 2026 | 728.79M |
| September 18, 2026 | 702.10M |
| September 17, 2026 | 728.79M |
| September 16, 2026 | 732.05M |
| September 15, 2026 | 752.20M |
| September 14, 2026 | 793.59M |
| Date | Value |
|---|---|
| September 11, 2026 | 751.11M |
| September 10, 2026 | 753.29M |
| September 09, 2026 | 802.03M |
| September 08, 2026 | 903.59M |
| September 04, 2026 | 900.87M |
| September 03, 2026 | 856.76M |
| September 02, 2026 | 885.07M |
| September 01, 2026 | 769.63M |
| August 31, 2026 | 760.91M |
| August 28, 2026 | 770.17M |
| August 27, 2026 | 818.09M |
| August 26, 2026 | 825.72M |
| August 25, 2026 | 844.23M |
| August 24, 2026 | 773.44M |
| August 21, 2026 | 808.84M |
| August 20, 2026 | 792.77M |
| August 19, 2026 | 820.82M |
| August 18, 2026 | 804.48M |
| August 17, 2026 | 789.78M |
| August 14, 2026 | 790.87M |
| August 13, 2026 | 805.02M |
| August 12, 2026 | 753.29M |
| August 11, 2026 | 821.36M |
| August 10, 2026 | 809.38M |
| August 07, 2026 | 825.72M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 522.06M |
| Amgen, Inc. | 277.12B |
| Anika Therapeutics, Inc. | 254.23M |
| BioCryst Pharmaceuticals, Inc. | 2.472B |
| Imunon, Inc. | 5.740M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -62.81M |
| Total Expenses (Quarterly) | 62.81M |
| EPS Diluted (Quarterly) | -1.157 |
| Earnings Yield | -462.5% |
| Normalized Earnings Yield | -160.93 |